Vaccines, Blood & Biologics
July 23, 2010 Approval Letter - FluLaval
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
Food and Drug Administration
Rockville, MD 20852-1448
July 23, 2010
Our STN: BL 125163/172
ID Biomedical Corporation of Quebec
Attention: LaDonna Nugent, M.S.
2301 Renaissance Boulevard
Building 510, P.O. Box 61540
King of Prussia, PA 19406-2772
Dear Ms. Nugent:
We have approved your request to supplement your biologics license application for Influenza Virus Vaccine (FluLaval), to include the 2010-2011 United States formulation.
Please submit all final printed labeling at the time of use and include implementation information on Form FDA 356h. Please provide content of labeling in Structured Product Labeling format. Please provide carton and container labeling in Structured Product Labeling format.
We will include information contained in the above-referenced supplement in your biologics license application file.
Sincerely yours,
/signature/
Jerry P. Weir, Ph.D.
Director
Division of Viral Products
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research
Attachment: Approved Final Draft Labeling







